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Propositions 
To the doctoral thesis 
Pharmacogenomics in Drug Development: 
Implementation and Application of PKPD Model Based Approaches 
 
1.  Incorporating PK-PD modelling into pharmacogenomics (PGx) research 
enables quantitation of the contribution of genetic variability relative 
to the overall interindividual variation. This thesis 
2. The relationship between genotype and phenotype should not only 
focus on the mean differences between genotype groups but also on 
the variation within each phenotype group. This thesis  
3. Clinical trial simulation can be used to quantitatively compare study 
designs incorporating genetic information, and will lead to improved 
therapeutic outcomes. This thesis  
4.  Genotype differences in pharmacokinetics should always be 
considered relative to the exposure response relationship. This thesis 
5. PB-PK models incorporating information from non-clinical sources 
should be used to optimise the design of first in human trials for drugs 
which undergo biotransformation by polymorphic enzymes (Jones H 
and  Rowland-Yeo K, CPT Pharmacometrics Syst. Pharmacol. 2013:2, 
e63). 
6.   Modelling PK, PD, PGx, and systems pharmacology will not only 
enhance the power of predicting a personalized drug response but will 
also shed light on our understanding of living systems in a broad sense 
(Xie L et al. PLoS Comput Biol. May 2014; 10(5)). 
7.  Genetic heterogeneity alone cannot completely explain interindividual 
variations in drug responses (Lam YW, ISRN Pharmacol. 2013:641089). 
8. For most drugs, pharmacogenomic testing has not been endorsed by 
expert committees, since we still lack evidence that clinical outcomes 
will improve (Kitzmiller J et al Cleve Clin J Med. Apr 2011; 78(4): 243–
257). 
9. Everything is theoretically impossible until its done (Robert A. Heinlein). 
10. Valid criticism does you a favour (Carl Sagan). 
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